Eli Lilly and Company (NYSE:LLY) Shares Sold by Horizon Kinetics Asset Management LLC

Horizon Kinetics Asset Management LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,116 shares of the company’s stock after selling 141 shares during the quarter. Horizon Kinetics Asset Management LLC’s holdings in Eli Lilly and Company were worth $3,647,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in LLY. Earnest Partners LLC increased its stake in Eli Lilly and Company by 13.8% in the first quarter. Earnest Partners LLC now owns 453 shares of the company’s stock valued at $352,000 after purchasing an additional 55 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in Eli Lilly and Company by 357.0% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 11,074 shares of the company’s stock valued at $8,615,000 after acquiring an additional 8,651 shares during the last quarter. Industrial Alliance Investment Management Inc. lifted its holdings in shares of Eli Lilly and Company by 2.6% during the first quarter. Industrial Alliance Investment Management Inc. now owns 1,602 shares of the company’s stock worth $1,246,000 after purchasing an additional 40 shares during the period. Icon Wealth Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 0.3% in the first quarter. Icon Wealth Advisors LLC now owns 9,250 shares of the company’s stock valued at $7,196,000 after acquiring an additional 24 shares in the last quarter. Finally, Oxford Wealth Group LLC acquired a new position in Eli Lilly and Company during the 1st quarter worth approximately $2,877,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.3 %

Shares of NYSE LLY opened at $750.50 on Monday. The firm has a market cap of $712.46 billion, a P/E ratio of 80.87, a price-to-earnings-growth ratio of 2.83 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The firm’s 50 day moving average price is $865.01 and its 200 day moving average price is $870.32.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same period in the prior year, the firm earned $0.10 EPS. Eli Lilly and Company’s revenue for the quarter was up 20.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 13.2 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.69%. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price for the company. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Finally, Wells Fargo & Company upped their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,007.94.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.